Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Par Pharmaceutical Companies, Inc. today announced that the United States Court of Appeals for the Federal Circuit has upheld the U.S. District Court ...
Par Specialty Pharmaceuticals, a division of Par Pharmaceutical, Inc., today announced the launch of Cortisporin®-TC Otic Suspension (colistin...
Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Friday, March 13, 2015 at 2:00 p.m. EDT to review its...
Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated ...
Par Pharmaceutical Companies, Inc. ("Par") today announced that it has entered into a definitive agreement to acquire JHP Group Holdings, the parent...
Par Pharmaceutical Companies, Inc. today announced that it has begun shipping dexmethylphenidate hydrochloride (HCl) 15 mg and 30 mg extended-release ...
Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Thursday, May 16, 2013, at 10:00 a.m. EDT to review its...
Par Pharmaceutical Companies, Inc. today announced that its operating subsidiary, Anchen Pharmaceuticals, Inc., has received final approval from the...
Par Pharmaceutical Companies, Inc., and TPG today announced the completion of Par's acquisition by certain affiliates of TPG. "This transaction has...
Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it will host a conference call and live webcast on Tuesday, May 8, 2012 at 9:00...
Par Pharmaceutical Companies, Inc. (NYSE:PRX) today announced that it began shipping all strengths of modafinil tablets, a generic version of Teva's...
Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has completed its acquisition of Anchen Pharmaceuticals, a privately-held...
Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it entered into a definitive agreement to acquire Anchen Pharmaceuticals, a...
Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported results for the first quarter ended March 31, 2010. For the first quarter ended March...
Strativa Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the new drug...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.